C-Biomex

What C-Biomex does

C-Biomex Co., Ltd is a preclinical-stage South Korean biotechnology company founded in 2017 and headquartered in Pohang-si, Gyeongsangbuk-do. The company develops radiopharmaceutical theranostics—agents that combine a targeting ligand with a radioisotope to enable both diagnosis and therapy of cancer—built on its proprietary CUS™ peptide discovery platform. The CUS™ platform applies a three-stage differentiated process: synthesis of a high-purity peptide library incorporating unnatural amino acids for serum stability, screening via a zwitterionic dye-coupled bead-peptide method that minimizes background interaction, and direct sequencing using COPAS and MALDI-TOF/MS equipment together with a proprietary analysis algorithm to identify peptides with high target selectivity and binding affinity.

The pipeline currently comprises four preclinical candidates spanning oncology and rare disease: CBT-001, a CAIX-targeting Peptide Receptor Radionuclide Therapy for renal cancer positioned as first-in-class with no approved therapeutic for the target and the most advanced program at R&D/preclinical stage; CBT-002, an SSTR2-targeting PRRT for neuroendocrine tumors designed as a pro-drug with claims of reduced normal-cell toxicity versus the approved Lutathera; CBT-004, a low-molecular D-peptide targeting FAP-α for solid cancers; and CBT-005, a D-amino-acid CNP peptide targeting NPR-B for achondrogenesis. R&D is supported by academic and institutional collaborations with Seoul National University, Johns Hopkins University, and the Korea Institute of Radiological & Medical Sciences.

C-Biomex is a privately-held, founder-owned bio-venture with no commercial revenue, pricing, or distribution channels disclosed. The business model is consistent with a preclinical radiopharmaceutical developer: future commercialization is expected through out-licensing, partnership, or acquisition by established pharmaceutical companies rather than direct sales. The company has raised a Series 2 funding round of approximately $5.0 million (June 2022) from a syndicate of Korean and venture investors including Mirae Asset Venture Investment, SHINPOONG.CO, Innopolis Partners, Enlight Ventures, E&Venture Partners, and Stassets Investment, and operates with 11-50 employees.

Name

C-Biomex

Legal name

CBIOMEX Inc.

Website

https://cbiomex.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

C-Biomex is a preclinical South Korean biotech developing radiopharmaceutical theranostics for solid tumors and rare diseases using its proprietary CUS™ peptide discovery platform, with four pipeline candidates including CAIX- and SSTR2-targeted programs.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals / Targeted Peptide Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Radiopharmaceutical development
• Peptide drug discovery
• Cancer theranostics
• Targeted radiotherapy
• Biotech drug development

Headquarters

HQ city

Pohang

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels3 records

Core offering

C-Biomex is a preclinical-stage biotech drug development company that discovers and develops radiopharmaceutical theranostics combining targeting peptides with radioisotopes for cancer diagnosis and treatment. Using its proprietary CUS™ peptide discovery platform, the company is advancing a pipeline of pipeline candidates (CBT-001, CBT-002, CBT-004, CBT-005) targeting CAIX, SSTR2, FAP-α, and NPR-B for solid tumors, neuroendocrine tumors, and rare skeletal diseases. Revenue is expected through future licensing, partnerships, or acquisition of its drug candidates by established pharmaceutical companies.

Product overview

C-Biomex is a bio-venture company founded in 2017 focused on advancing novel theranostics using its proprietary peptide discovery platform technology CUS™. The company develops a portfolio of radiopharmaceutical candidates including CBT-001 (CAIX-targeting for renal cancer), CBT-002 (SSTR2-targeting for neuroendocrine tumors), CBT-004 (FAP-α-targeting for solid cancers), and CBT-005 (NPR-B-targeting for achondrogenesis). These pipeline candidates utilize Peptide Receptor Radionuclide Therapy, PDC, and Pro-drug approaches combining peptides with radioisotopes for targeted cancer diagnosis and treatment.

Differentiator

Problem solved

Functional benefit

Products and services

• CBT-001 Peptide Receptor Radionuclide Therapy targeting CAIX for renal cancer. A radioactive diagnostic and therapeutic agent combining peptides that selectively bind to CAIX protein with radioisotopes, designed to maximize therapeutic effect while minimizing toxicity to normal cells. Intended for renal cancer and other solid tumors expressing CAIX.
• CBT-002 Peptide Receptor Radionuclide Therapy targeting SSTR2 for neuroendocrine tumors. Features a pro-drug structure designed to lower toxicity to normal cells and increase specificity to cancer cells compared to Lutathera.
• CBT-004 PRRT, PDC, and Pro-drug candidate targeting FAP-α for solid cancers. A low-molecular D-peptide designed to effectively inhibit FAP-α with superior stability and selectivity compared to other quinolone-based low-molecular compounds.
• CBT-005 Peptide CNP targeting NPR-B for achondrogenesis. Uses D-amino acid for increased stability in the body, with cartilage-specific targeting and strong NPR-B binding through material advancement.

Quantifiable outcome

• CBT-001 strongly binds to cancer cells and maintains high concentration for extended duration to maximize therapeutic effect
• +2 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• TrioarminorStrategic or Co-development PartnerR&D/Industry partnership for new drug development through cooperative research
• EflaskminorStrategic or Co-development PartnerR&D/Industry partnership for new drug development through cooperative research
• PortraiminorStrategic or Co-development PartnerR&D/Industry partnership for new drug development through cooperative research
• Pohang Techno ParkminorStrategic or Co-development PartnerR&D/Industry partnership for developing innovative treatments through cooperative research
• Seoul National UniversitycoreStrategic or Co-development PartnerAcademic R&D partnership including collaboration with Professor Kang Keon-wook from Seoul National University Medical Research Center for preclinical and clinical development consulting on CBT-001 and CBT-004 anticancer drugs
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerAcademic R&D partnership with Professor Min-il for joint research on solid cancer treatments and preclinical support for platform and CBT-001, involving innovative research in CAR-T and Bio-Radiopharmaceutical Therapy
• Korea Institute of Radiological & Medical SciencescoreStrategic or Co-development PartnerR&D/Academy partnership for radiopharmaceutical development and research cooperation

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Novartis: Global pharmaceutical company with Lutathera, the leading approved SSTR2-targeted Peptide Receptor Radionuclide Therapy for neuroendocrine tumors — the same target as C-Biomex's CBT-002. Establishes the incumbent benchmark for radiopharmaceutical cancer therapy that C-Biomex must differentiate against.
• Lantheus Holdings: Established radiopharmaceutical company with a portfolio of diagnostic and therapeutic agents including POINT-targeted and PSMA programs. Direct modality peer that demonstrates the commercial scaling required to monetize radiopharma assets at scale.
• Bayer (Xofigo franchise): Major pharma with Xofigo (radium-223), the first approved alpha-emitting radiopharmaceutical for cancer, and ongoing investment in radioligand therapy via acquisitions and partnerships. Represents large-pharma competitor and potential partner/acquirer for radiopharma assets.

Direct peers

• Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company developing targeted imaging and therapy agents across oncology indications including renal cancer (TLX250, CAIX-targeted). Most direct comparable to C-Biomex's CBT-001 and provides a benchmark for radiopharma development path and valuation.
• PeptiDream: Japan-based peptide discovery platform company using proprietary technology to identify non-standard peptides for therapeutic use, including radioligand therapy collaborations with large pharma. Closest peer in terms of proprietary peptide discovery engine analogous to C-Biomex's CUS™ platform.
• Bicycle Therapeutics: Clinical-stage company developing bicyclic peptide therapeutics for oncology, including toxin-conjugated and radioligand programs. Compares to C-Biomex as an engineered peptide platform pursuing targeted cancer therapy with similar modular drug-conjugate approaches.
• RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225-based targeted radiotherapies for solid tumors; acquired by Bristol Myers Squibb in 2024 for $4.1B. Validates the platform-plus-pipeline radiopharma model C-Biomex aspires to and represents a likely exit path via acquisition.
• Point Biopharma: Radiopharmaceutical company developing targeted radioligand therapies for cancer, acquired by Eli Lilly in 2023. Comparable to C-Biomex in modality (radioligand therapy) and therapeutic ambition, illustrating large-pharma appetite for clinical-stage radiopharma platforms.
• ITM Isotope Technologies Munich: Radiopharmaceutical company developing targeted radionuclide therapies and diagnostics, with proprietary isotope manufacturing capacity. Comparable to C-Biomex as a specialized radiopharma player where C-Biomex would likely need isotope supply partnerships to advance candidates.

Regional players

• LegoChem Biosciences: Korean biotech developing antibody-drug conjugates and peptide-drug conjugate platforms; former employer of C-Biomex's CFO. Comparable regional peer in Korean biotech ecosystem with overlapping peptide/ADC technical approaches and investor base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/100040878132579

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about C-Biomex